Left Ventricular Diastolic Dysfunction Is Associated With the Prevalence of Paroxysmal Atrial Fibrillation Determined

Takashi Akima1, Katsutoshi Sekine2, Koki Yamaoka1

  • 1Department of Cardiology, Saitama-Municipal Hospital Saitama Japan.

Circulation Reports
|March 11, 2021
PubMed

Insights

Left ventricular diastolic dysfunction (LVDD) severity, graded by echocardiography, is linked to paroxysmal atrial fibrillation (PAF) prevalence. Higher LVDD grades, especially Grade 3, show a significant association with PAF, suggesting potential new therapeutic markers.

Area of Science:

  • Cardiology
  • Echocardiography
  • Cardiac Electrophysiology

Background:

  • The link between left ventricular diastolic dysfunction (LVDD) and paroxysmal atrial fibrillation (PAF) is not well-defined due to a lack of standardized LVDD assessment.
  • Current American Society of Echocardiography guidelines offer a framework for grading LVDD, enabling more precise investigation.

Purpose of the Study:

  • To investigate the association between LVDD severity, categorized by the latest echocardiographic criteria, and the prevalence of PAF.
  • To explore if LVDD grading can serve as a predictor for PAF development.

Main Methods:

  • A retrospective analysis of 2,063 patients without persistent atrial fibrillation who underwent echocardiography.
  • Patients were classified into six LVDD categories: No-LVDD, Borderline, Grade 1, Indeterminate, Grade 2, and Grade 3.
  • PAF prevalence was calculated for each LVDD grade, with multivariate analysis adjusting for patient characteristics.

Main Results:

  • PAF prevalence was significantly higher in patients with Grade 3 LVDD (54.5%) compared to other grades.
  • In patients with reduced left ventricular ejection fraction, PAF prevalence increased proportionally with LVDD grade.
  • Multivariate analysis confirmed a significant association between LVDD severity and PAF prevalence.

Conclusions:

  • LVDD severity, as determined by current echocardiographic guidelines, is associated with the prevalence of PAF.
  • These findings highlight the potential of LVDD assessment as a tool for identifying patients at risk for PAF and developing novel therapeutic strategies.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
181
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
251
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
138
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
139
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
135
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
79